Advertisement
Singapore markets closed
  • Straits Times Index

    3,292.69
    +10.64 (+0.32%)
     
  • Nikkei

    38,405.66
    +470.90 (+1.24%)
     
  • Hang Seng

    17,763.03
    +16.12 (+0.09%)
     
  • FTSE 100

    8,144.13
    -2.90 (-0.04%)
     
  • Bitcoin USD

    62,955.66
    -677.18 (-1.06%)
     
  • CMC Crypto 200

    1,285.73
    -53.33 (-3.98%)
     
  • S&P 500

    5,065.00
    -51.17 (-1.00%)
     
  • Dow

    37,949.13
    -436.96 (-1.14%)
     
  • Nasdaq

    15,790.56
    -192.53 (-1.20%)
     
  • Gold

    2,305.90
    -51.80 (-2.20%)
     
  • Crude Oil

    81.87
    -0.76 (-0.92%)
     
  • 10-Yr Bond

    4.6740
    +0.0600 (+1.30%)
     
  • FTSE Bursa Malaysia

    1,575.97
    -6.69 (-0.42%)
     
  • Jakarta Composite Index

    7,234.20
    +78.41 (+1.10%)
     
  • PSE Index

    6,700.49
    -69.15 (-1.02%)
     

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Organogenesis Holdings Inc.
Organogenesis Holdings Inc.

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.

“We are very pleased with the Court's decision,” said Lori Freedman, Chief Administrative and Legal Officer for Organogenesis. “We are happy to have this behind us so we can continue to focus on our mission to substantially improve patient outcomes while lowering the overall cost of care.”

About Organogenesis Holdings Inc.

ADVERTISEMENT

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

CONTACT: Investor Inquiries: ICR Westwicke Mike Piccinino, CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis communications@organo.com